Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-01-25
2011-01-25
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S617000
Reexamination Certificate
active
07875652
ABSTRACT:
The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.
REFERENCES:
patent: 4303673 (1981-12-01), Biedermann et al.
patent: 4510082 (1985-04-01), Gesellchen et al.
patent: 4513009 (1985-04-01), Roques et al.
patent: 4533657 (1985-08-01), Morgan
patent: 4618708 (1986-10-01), Roques et al.
patent: 4707468 (1987-11-01), Yoshino et al.
patent: 5378729 (1995-01-01), Kohn et al.
patent: 5508266 (1996-04-01), Fink
patent: 5536853 (1996-07-01), Spellmeyer et al.
patent: 5585358 (1996-12-01), Bialer et al.
patent: 5654301 (1997-08-01), Kohn et al.
patent: 5656267 (1997-08-01), Sagen et al.
patent: 5760038 (1998-06-01), Murugesan et al.
patent: 5773475 (1998-06-01), Kohn
patent: 5780589 (1998-07-01), Lazarus et al.
patent: 5885999 (1999-03-01), Elliott et al.
patent: 6001876 (1999-12-01), Singh
patent: 6028102 (2000-02-01), Bialer et al.
patent: 6037324 (2000-03-01), Schwender et al.
patent: 6083941 (2000-07-01), Farb
patent: 6083951 (2000-07-01), Bradbury
patent: 6103732 (2000-08-01), Amberg et al.
patent: 6114390 (2000-09-01), Engel et al.
patent: 6126939 (2000-10-01), Eisenbach-Schwartz et al.
patent: 6180611 (2001-01-01), Montana et al.
patent: 6277825 (2001-08-01), Olivera et al.
patent: 6737408 (2004-05-01), Balasubramanium et al.
patent: 6803481 (2004-10-01), Selve
patent: 6884910 (2005-04-01), Harris
patent: 2002/0052418 (2002-05-01), Shirvan et al.
patent: 2003/0216466 (2003-11-01), Scheuerman et al.
patent: 2004/0101582 (2004-05-01), Wolicki
patent: 2004/0204495 (2004-10-01), Shirvan et al.
patent: 2005/0013856 (2005-01-01), Trivedi et al.
patent: 2005/0043675 (2005-02-01), Pastore et al.
patent: 2005/0209163 (2005-09-01), Stoehr
patent: 2005/0227961 (2005-10-01), Kucharik et al.
patent: 2005/0261204 (2005-11-01), Stoehr
patent: 2005/0288234 (2005-12-01), Stoehr
patent: 2006/0009384 (2006-01-01), Rudd et al.
patent: 2006/0046957 (2006-03-01), Beyreuther et al.
patent: 2006/0100157 (2006-05-01), Rauschkolb-Loffler et al.
patent: 2006/0135437 (2006-06-01), Stoehr et al.
patent: 2006/0252749 (2006-11-01), Stohr
patent: 2007/0042969 (2007-02-01), Rauschkolb-Loffler et al.
patent: 2007/0043120 (2007-02-01), Beyreuther et al.
patent: 2007/0048372 (2007-03-01), Beyreuther et al.
patent: 2007/0054962 (2007-03-01), Selve
patent: 2007/0197657 (2007-08-01), Beyreuther et al.
patent: 2008/0027137 (2008-01-01), Riedner et al.
patent: 2008/0287545 (2008-11-01), Scheller et al.
patent: 2009/0018197 (2009-01-01), Rudd et al.
patent: 2009/0018198 (2009-01-01), Stohr
patent: 195 33 023 (1996-04-01), None
patent: 0 555 537 (1993-08-01), None
patent: 0 997 147 (2000-05-01), None
patent: 1243263 (2002-09-01), None
patent: 1 243 263 (2002-11-01), None
patent: 1 486 205 (2004-12-01), None
patent: 1 486 206 (2004-12-01), None
patent: 1 537 862 (2005-06-01), None
patent: 1 541 138 (2005-06-01), None
patent: 1 579 858 (2005-09-01), None
patent: 1 688 137 (2006-08-01), None
patent: WO 92/14706 (1992-09-01), None
patent: WO 95/30645 (1995-11-01), None
patent: WO 96/11209 (1996-04-01), None
patent: WO 96/32100 (1996-10-01), None
patent: WO 9632100 (1996-10-01), None
patent: WO 97/38980 (1997-10-01), None
patent: WO 97/38981 (1997-10-01), None
patent: WO 98/09953 (1998-03-01), None
patent: WO 99/02146 (1999-01-01), None
patent: WO 99/07413 (1999-02-01), None
patent: WO 99/16444 (1999-04-01), None
patent: WO 99/23078 (1999-05-01), None
patent: WO 99/43309 (1999-09-01), None
patent: WO 99/56761 (1999-11-01), None
patent: WO 9965903 (1999-12-01), None
patent: WO 00/51586 (2000-09-01), None
patent: WO 01/17976 (2001-03-01), None
patent: WO 01/78762 (2001-10-01), None
patent: WO 02/13766 (2002-02-01), None
patent: WO 02/15922 (2002-02-01), None
patent: WO 02/42256 (2002-05-01), None
patent: WO 02/074297 (2002-09-01), None
patent: WO 02/074784 (2002-09-01), None
patent: WO 02/076979 (2002-10-01), None
patent: WO 02/087548 (2002-11-01), None
patent: WO 02/088664 (2002-11-01), None
patent: WO 03/000642 (2003-01-01), None
patent: WO 2004/014895 (2004-02-01), None
patent: WO 2004/043926 (2004-05-01), None
patent: WO 2004/046178 (2004-06-01), None
patent: WO 2004/060353 (2004-07-01), None
patent: WO 2004/066987 (2004-08-01), None
patent: WO 2004/066990 (2004-08-01), None
patent: WO 2004/091585 (2004-10-01), None
patent: WO 2004/100871 (2004-11-01), None
patent: WO 2005/053667 (2005-06-01), None
patent: WO 2005/092313 (2005-10-01), None
patent: WO 2005/099740 (2005-10-01), None
patent: WO 2005/120539 (2005-12-01), None
Hama et al. “NMDA-induced spinal hypersensitivity is reduced by naturally derived peptide analog[Ser']histogranin,” Pharmacology Biochemistry and Behavior, 1999, vol. 62, No. 1, pp. 67-74.
Definition of allodynia, http://www.medterms.com/script/ain/art.asp?articlekey=25197.
Definition of allodynia, http://www.medterms.com/script/ain/art.asp?articlekey=25197, 2006.
Abbott et al. (1995) Pain 60:91-102.
Abdulla & Smith (2002) J. Neurophysiol. 88:2518-2529.
Akiba et al. (2003) Receptors & Channels 9:291-299.
Amir et al. (2006) J. Pain 7(5 Suppl. 3):S1-S29.
Arnér & Meyerson (1988) Pain 33:11-23.
Arnt et al. (1984) Pol. J. Pharmacol. Pharm. 36:221-230.
Arroyo (2003) “Safety of SPM 927 in subjects with epilepsy and neuropathic pain” Poster presented at AES Scientific Exhibit, Dec. 5-10, 2003.
Backonja (2002) Neurology 59:S14-S17.
Backonja (2003) Anesth. Analg. 97:785-790.
Béguin et al. (2003) Bioorganic & Medicinal Chemistry 11:4275-4285.
Béguin et al. (2004) Bioorganic & Medicinal Chemistry 12:3079-3096.
Ben-Menachem (2005) “A dose-response, placebo-controlled trial using lacosamide as adjunctive therapy in subjects with partial seizures” Presented at 26th International Epilepsy Congress, Paris, Aug. 28-Sep. 1, 2005.
Ben-Menachem et al. (2005) “Efficacy and safety of adjunctive oral lacosamide for the treatment of partial-onset seizures in patients with epilepsy” Poster P03.101 presented at American Academy of Neurology 57th Annual Meeting, Miami Beach, FL.
Bennett & Xie (1988) Pain 33(1):87-107 (abstract only http://www.ncbi.nlm.nih.gov/pubmed/2837713).
Bennett et al. (2000) Pain 86:163-175.
Beyak et al. (2004) Am. J. Physiol. Gastrointest. Liver Physiol. 287:G845-G855.
Beyreuther (2004) “Pharmacology of SPM 927 and its relevance to clinical practice for neuropathic pain” Presented at Visiongain Pain Management, 2004.
Beyreuther et al. (2004) “SPM 927 displays potent antinococeptive effects in rat models for inflammatory and neuropathic pain” Poster presented at Neuropathic Pain, May 13-14, 2004.
Beyreuther et al. (2006) “Effects of lacosamide as compared to other analgesics: a responder analysis in the streptozotocin rat model for diabetic neuropathic pain” Poster 618 presented at American Pain Society, 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster id=2637#618).
Beyreuther et al. (2006) “Lacosamide displays antinociceptive effects in a rat model for musculoskeletal pain induced by TNF” Poster 625 presented at American Pain Society, 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster—id=2643#625).
Beyreuther et al. (2006) “Lacosamide displays antinociceptive effects in rat models for arthritis pain” Poster 626 presented at American Pain Society, 2006 (abstract at http://www.ampainsoc.org/db2/abstract/view?poster—id=2644#626).
Beyreuther et al. (2006) Eur. J. Pharmacol. 539:64-70.
Beyreuther et al. (2007) CNS Drug Rev. 13(1):21-42.
Beyreuther et al. (2007) Arthritis Res. Therapy 9:R14, http://arthritis-research.com/content/9/1/R14.
Bialer et al. (2001) Epilepsy Res. 43:11-58.
Bialer et al. (2002) Epilepsy Res. 51:31-71.
Bilsky et al. (2000) J. Med. Chem. 43:2586-2590.
Biton et al. (2003) Epilepsia 44(Suppl. 9):259, abst. 2.241 (poster attached).
Biton et al. (2004) &
Harness & Dickey & Pierce P.L.C.
UCB Pharma GmbH
Wang Shengjun
LandOfFree
Method and composition for treating pain or tinnitus aureum does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for treating pain or tinnitus aureum, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating pain or tinnitus aureum will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694095